AUPH - Earnings call transcript Q4 2020 | Aurinia Pharmaceuticals Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings and welcome to the Aurinia Year End 2020 Financial Results Conference Call. [Operator Instructions] It’s now my pleasure to turn the call over to Glenn Schulman, Senior Vice President, Investor Relations. Please go ahead, sir.

Glenn Schulman

Thank you, Kevin and good afternoon everyone. I am pleased to welcome you to today’s call discussing Aurinia’s fourth quarter and year end financial results.

and call Aurinia; are Medical Neil Colao, Commercial the and Greenleaf, Officer; on Chief Chief of our CEO Solomons, Officer; me this Peter afternoon President Max Financial Joining Officer. Miller, Joe our Chief Form issued as www.auriniapharma.com after financial announcing filed and recent highlights, has we and well. from accessible a press which release been This afternoon, is p.m., X-K our our SEC just operational X with our the results website on at

also property the statement is and Annual Investor without financial being note today’s discussion call be or and XX-K. We would will our Aurinia. our also on recorded, obtained of of from remind Relations that Aurinia. is management’s completion approximately available hours analysis in Please a replay today’s Report I after content the Aurinia’s X filed and webcast may live call written Form consent on website transcribed everyone like the to reproduced not It prior be call. of today’s that

please expectations. subject free of and forward-looking during Schulman Also, risks out e-mail reach this via statements feel forward-looking actual our our to to number may and ir@auriniapharma.com. Glenn course on current we based results me, may at statements of call, to make a materially. These are the uncertainties approval, significant For differ

please required and and turn call today, all XXXX With and our as is our are release the any Greenleaf, law, future Securities me this upon and now which Securities our of Exchange business, results CEO. that, by along press such update with all of statements affect Annual current over are please President as statements Form we the available to financial that Also as For the call Canadian filings discussion Peter based during us. no today most our that Aurinia’s the to to and disclosure assume February factors Commission let Except with XX, obligation available Authorities. a in of information could of currently of Report U.S. note publicly refer recent XX-K and our to on made date. Peter?

Peter Greenleaf

XX Thanks, you an introduce business the to as professionals in launch recapping joining is our busy just days LUPKYNIS and was healthcare folks. patients to fourth a This update this agenda of will what’s on straightforward, pretty as today. next thank we call Today’s Glenn post-approval afternoon, happening all and as sharing what we product for company, XXXX what’s well quarter for and be very the of market. U.S. continue

into the the providing capacity cost manufacturer provides capacity in demand. Of security our launch will existing we the switch with label is agreement The finalizing up and the obviously to existing also internal to is fourth production the future commercial around market. at deliver to button. the or negotiations, work a where ability expand and our voclosporin, to dedicated course, quite long-term shore the know out year. world. a at not Lonza quarter meeting as the to well on ship with update all close flipping and launch LUPKYNIS build December announced readiness prep, financially facility We product busy also and to hard were agreements and collaborative company’s XXXX, molecule product important U.S. preparing global launching facility are to a dedicated market We provide pushing we expanding as small The Switzerland. XX, supply launch simple while Visp, manufacturing we API beyond a On meet product of markets we within as for efficiency an

beyond company a announced days an XX, and Japan. Otsuka December with a to market to the all actions we overall Just global voclosporin expertise the higher compound that on and product and value voclosporin of even and increasing both a finalized we it take can in and levels These partnership nephrology Europe U.S. the focus on its while later, to the potential. strong ensure X Pharmaceuticals, moving ex-U.S. develop with global

in EU of Aurinia cost And regulatory the in payment the back the reimbursement of receive agreement, successful part manufacturing partnership, ensure double-digit the with this with upfront additional share $XX relationship received with million outcomes $XX deal, milestones. partner. has is Otsuka to recall, post an market will in the you as As royalties Aurinia an working Japanese and a authorities. of Through potential to and end our million plus approvals and with we and closely regulatory

already Otsuka and with Aurinia half have file fact, of and and our with on met along target MAA the remain January co-repertoire to voclosporin we EMA, in In XXXX. early in first the the repertoire

Agency, voclosporin Devices also Medical are PMDA the strategy and application to a We Japan. working and an with with Pharmaceuticals Otsuka submitting execute for in or to interacting optimal

this, of the been the with are course, provide team’s out we Max on with to track right the specifics but will we U.S. on midst to of All LUPKYNIS progress of want say happening where more commercial the of has to-date, be Colao in launch. gate. it’s safe

extension with we anticipate the end AURORA begin pediatric blinded and on sales on of hard we to stop of teams medical upcoming primary and to data meetings half Aurora studies work doesn’t research Also clinical X data remain the team first Furthermore, X by additional and company well publication, their And display line during results XXXX the our the track. as trial at the wait obligations, estimate XXXX. at post-approval, The first database achieving reporting meet the as year. the preparing year opportunities marketing remains finalizing do post-marketing major course continuous to the just lock this year. in and working and magic. quarter of manuscript development top and addition, Of in for voclosporin for adolescent which

that LN indication. leverage base Lastly, voclosporin new evaluate we continue to areas our options further to in strengthen development of

also and an I work. our bolster Aurinia work ability as weather portfolio am to pipeline this our better unprecedented with turn and our detail will only drive and see financial deeply Officer, IP remain year winter you impressed After Max “normalcy.” expect to Joe things new our to the development and I Commercial within and that in strive pandemic fluid we about over as will business quarter team’s operate provide and we return team innovation provide on We Chief to everyone fourth the Miller the some through to through get have will end their and that, activities. the on product CFO, development we the do adaptable to begin improve more conditions Colao, commercial who externalization now seen we the a update results. call will

with let me the So call that, to turn Max? over Colao. Max

Max Colao

Thank good you, afternoon everyone. and Peter

XX as because career. pretty am old, good the And launch the you guess if actually achieved this and I have that’s over amidst point, what but I in an am proves making my nothing number. a by a month And just to saying launch. happy am I with the were that of our we since ways share has else, that I admirable the past other approval none it XXth I is to So see disease. might begin stepped is in XX, do I done challenge pandemic. we commercial that way. the launched the those a minute, what the rare transformative up time Of in before. There therapies team never And will lot as have this you been had this a a is COVID have fourth we with all very unprecedented hear have for as in environment to

As changed, many know, the even market a amidst COVID. Those of for world are therapy launching haven’t dynamics that a from drive a population. dynamics apart patient larger you such

stage can can everyone’s provide prescription interest and appreciate response. of numbers am been related Even comments at to numbers tracking so, certainly such prescription sure I will this while market volume. I you appreciate amidst our we So, environment this say expectation. genuinely The the of are hearing that have that a with indicator in I initial level pleased good can counts, to early

fact, important around will next little be it metric a meantime what we position they to were at But on about early the even to are executing we is highlight very ahead this more a certainly In feel positive in initial we obviously and anything, if our of strategy. anticipating. our today, call. entirely early this in progress In the reasonable share details our stage, trend

execute ensure has are these the to and What showcases a can there Alliance of our right standard Just our short January gain outcomes, delays critical four in LUPKYNIS. goals. was on to strategy late patients have ensure strongly was these XX channel. and a Achieving Aurinia all of LUPKYNIS in time approval ensure patients prescriptions success access as critically ability care, own four strategic in to approved to LUPKYNIS LN, planks: minutes. is diagnosis amount Friday, on optimal LUPKYNIS. of early our towards receive of XX the objectives refresh, hours that Monday later, was following no within XX. the online achieved establish receiving we LUPKYNIS of

physicians. to virtual, in-person keep response interest powered sales was Interestingly, have and the been fully weather know the team field XX% commitment. team that very within team. been local COVID the like the has sleet, It trained with very what speaks of have incredible live way. dedication has field make guidelines. XX% on fully in of think indicate appointments high and compliant of positive. approval. We restrictions, our great of not snow, We robust also LUPKYNIS confirms get far the been of Talk part in about and has in-person, been from energy all Our calls ratio rain, and and this letting tenacity and physician to to Reports context so our that deployed of hours not our on calls this the

as experienced. before, from have I novices. high discussed are us a They are the as individuals the field. team hold feedback on a know them not stakes They and sharing for of to genuine very As for ours back company is

sales That real-time are seen is who of degree team encouraging. our specificity obviously for fact, patients during actually identify and call, candidates In likely LUPKYNIS. has many thought physicians in the

which up over so not only prescriber We individual more but set include staff clinics, for starting XX% our base. lupus at to calls prescribing. X,XXX professionals get have completed These on of far, than LUPKYNIS healthcare clinical are practitioners, reaching

lives. interactions launch. when to met skillful will of We with the since execution. with completed insured XX% and That And just scheduled meetings, weeks have nation’s speak does X insured representing we really of covering XXX XX% payers million in upcoming payers, complete our also intense that’s we lives Yes, have lives.

and the very early but gratifying. incredibly our response importantly, been patient awareness has to Finally, launch

by will that I you two from with posts think fact, say sharing media all. I close In it social

sister My This may a many you. first thank experience. complications means from other that years that ago, of died go lupus as through The to you, have nephritis. thank says thank you, result wrenching families not

thanks begins, post to Another the Almighty.

this our highly that venues. answered Joe? creating very Thank continue only fertile the the have we and Thank and many These look Aurinia to Joe he are is an environment our you, for financials. people’s confidence further has Finally, accelerated Pharma, to also but you. not a is comments hearing prayers. vigorous, typical review we that to execution a I confirm inspire through Alliance the turn Aurinia launch. Happily, seeing responses it of other forward they of us, will strategy now over And successful updates. I for extremely

Joe Miller

Thank you, Max. everyone. Good afternoon,

$XXX that cash manufacturing cash, include $XX.X had XXXX. programs million the at the year As million $XX.X least and XXXX compared December conducting of December The to to had company used December activities XX, XXXX. Aurinia December equivalents launch compared for plans, operating which in was and of plan operating to fund packaging commercial cash at and XX, financial resources commercial drug R&D year $XXX its for believes million XX, our ended Net investments million ended activities, it of sufficient current XX, XXXX. supply into funding XXXX,

December and expenses FDA to supply business XX, years XXXX the and loss manufacturing drug the development and consolidated XX, $X.XX and $XX.X organization, third-party partially For and ending share. per other offset $XXX.X XXXX December of the year million The of $XXX,XXX in research the in for due for regulatory in and respectively. in advance included Otsuka for contract costs expenses to Revenues an the expenses an XXXX. primary of XX, year million decrease net the Aurinia in XXXX. compared of professional of were the compared ended or increase million share-based Aurinia common primary The costs, and employee related $XX.X $XX.X $XX.X prepared salaries a Research a license build out December XXXX approval. December in for million million increase to for the XX, recorded the XXXX million decrease year year as received commercial Corporate, the $XX.X from infrastructure XX, of was fees was driver the lower upfront million XX, development R&D year for December year. payment as by expense clinical ended XXXX million CRO $XX revenue of to $XX.X in was licensing $XX ended of increase quarter during approval, XXXX, driver million the The administration December XXXX, ended million, in compensation which fourth and incurred expenses, ended decreased trial of XXXX. increase for spend increased recorded to $X.X benefits,

ended loss of XXXX. related for the the ended ended and driver XXXX Corporate, would December third-party like $XX months $XXX,XXX commercial clinical compensation closing for FDA some X to per an increase December hand for decreased increase regulatory offset share. professional share-based included and as $XX fees $XX.X months to The payment for costs, expenses spend decrease other build and approval. expense Revenues remarks. by primary months or XXXX upfront the XX, Aurinia million decrease months and development R&D $XX.X costs drivers for million the X $X.X for X XXXX expenses to aforementioned XXXX for $X.XX million due the compared R&D ended CRO Aurinia to XXXX, XXXX, million. supply the X consolidated months $X.X prepared X X expenses, in business in call XX, slight $XX.X the With million XXXX to December primary Peter out employee XX, partially XX, for a in recorded the increase in in manufacturing was XX, expenses and lower $XX I increased million advance of respectively. ended Otsuka XXXX ended The the an and for was back license quarter. in million from drug $XX.X of trial December a and received of in XX, compared Peter? December administration were XXXX. the of net of increase salaries months million in The which was approval, December that, infrastructure our common the For throughout million incurred to over to benefits, the

Peter Greenleaf

Thanks, And us, Joe. us today. Thank you, Max. joining thank giving your you all for time

voclosporin. also underway, – half with into partnership look launch. hear we on With with that additional will a be filing with surrounding continued line we are we to clinical ex-U.S. XXXX working the year LUPKYNIS forward want expand internal presentations development with to Europe MAA with projections to you including the launches the busy territories, the want our by first them medical Furthermore, the to upcoming with year. of you our bottom we track U.S. for us of Otsuka, hear from

to months exploring to enhance pipeline additional and forward We our by opportunities quarters to to also updates providing work and come. in to value look expand we the continue

As work opportunities I stated we enhance exploring earlier, to by expand our to continue value new to pipeline.

launch to we the the the to months look providing As additional in updates quarters come. progresses, and forward in U.S.

questions. your Operator? to with any open to So up like of I would it that,

Operator

Cantor you. Thank is question [Operator first Young Instructions] coming Fitzgerald. Alethia today from from Our

is line Your now live.

Unidentified Analyst

was continuously or feel to in the do Hi, maybe getting think you motivation? how going for these patients Do for the their to physicians Thanks a about challenge treatment you. my getting on a terms you of during bit anticipate this question. pandemic? like get lupus are of treatment patient population [indiscernible] nephritis you Thank is patient taking Alethia. I wondering

Peter Greenleaf

Max, Yes. experience hearing have that what troops, Since won’t Max, he we with we field project I on ask the now, ground will is seeing? are from I our what

Max Colao

United it’s Thanks for say variable that across States. thanks. the would Yes, question. I Yes, the

We visits. hearing line are actively through we them that that their also getting patients of are are of patients for are physicians engaged definitely their or in telemedicine but in delaying visits, hearing either

seeing confidence patient from variable the that So, are take in seeing opportunity it there. it’s we the U.S., doesn’t away our again but – is across

Unidentified Analyst

Okay, you. thank

Operator

you. Thank

is Our Cacciatore coming today Cowen Company. from next question from & Ken

now is line live. Your

Ken Cacciatore

guys. Hey,

early I the was to also, couple getting that any able is with questions. more that’s seeing going And there in early nuance Is care the Aurinia on be is have handled? exemption is managed some that written, or to and just there? the and there? there net prescriptions around nuance engagement? the know silly, the smoothly some for reason just if product thoughts Just the guidance had system wondering And just us much. take early of you’ve be patients successes a how if I patients of question us sharpen have know spending patients some then wondering with help to getting but on I medication sound if you to also a bit are little Alliance, to bit this patients you wanted $XX,XXX now could wondering year, that is just whole actually how any Thanks qualify to pricing additional little you a I any to that? the sorry, before going – Second for gave going, a am glitches process medical to so kind or

Peter Greenleaf

bookends on this And Ken. one. Thanks, take I will the

want assumptions, at to tell, it’s I the keep to currently it are net our place. put as in end pertains early the we of is think getting And think policies price I still think it’s too the to I where assumption it. day,

tuned you the exemption medical two, to will and following want things take keep Max, as progress. the other? question the we it So

Max Colao

have also payer payers their that number tell they the of more of all appreciated patients they of of care. you They to lives. And have in appreciated a we have that our covered can the and small than standard clinical And appreciated really Yes. voclosporin about relative economic burden offers interactions, that the are – that talking LN. also have I

So we payer now interactions. have And across that segment. encouraged tell prescriptions been we that with you are can reimbursed every our have I

prescriptions from that prescription rare And have federal also you any tell would where does So, we prescription – commercial launch the side, the going Medicare, other are rare Medicaid, definitely that on time. on you and reimbursed disease government. consistent look also I payers and on disease adjudication the our some with like to of well, we this what working seeing kind approvals that takes finalizing through as expect very launch. on in

Peter Greenleaf

And the expense to you one Joe, on want take guidance?

Joe Miller

Yes. Thanks Peter. Yes.

So, the infrastructure. kind – build-out commercial we freely the of as our will are run-rates QX have of spoken, previously burdened with

So estimate it’s looking I of you QX kind forward. will try probably where best reasonable are about we you give back look forward, and a and going will to at

numbers to specifically good but look happen target going to We what’s would haven’t in quarters guided the that the point a come. to of to yet, future kind be

Ken Cacciatore

Thanks much. Great. so

Peter Greenleaf

Ken. Thanks,

Operator

Jefferies. coming from question Maury is next today from Our Raycroft

Your now live. line is

Maury Raycroft

everyone. Hi, Thanks for taking my question.

whether in on centers. those? are community you of uptake question, primarily wondering going are additional you more this, getting much comment can are first on be on So naïve on types patients but how getting generally if just are able you to am Any patients or to if not off-label sure academic I switches you the from generics or perspective the more treatment say and LUPKYNIS

Peter Greenleaf

Max, jump in. right

Max Colao

Sure.

the for So, seeing are for. insights question. on have too any of deep prescriptions the patients we early to It yes, Maury thanks is that for types us

me was, definitely get of tell part as We have the… when, your our more we question And call. the into second will next

Maury Raycroft

versus Academic community.

Max Colao

community having we the side. more definitely No, on access are

down. expect areas centers, locked heavy can you in As are especially COVID academic pretty

but making inroads. So, are we

are we side. We but community inroads access making definitely both, better have the across on

Maury Raycroft

it a more Got the updated? get and it. potential published? about question priority is talk to second Thank on you. was getting on, contingent just And X data Phase KDIGO Is you if can guidelines this the

Peter Greenleaf

know those in Neil on I because Neil, is Solomons Dr. are call. progress. the

guidelines maybe give Neil, update manuscript? So, in to want an on the you

Neil Solomons

good in why I with is I is And have helpful. point. introduction Yes, that’s years sort be and on to the that’s in we guidelines. we that KDIGO said are refers But guidelines it publication it’s and mean, literature right. for data right, are the mean, I manuscript guidelines a you also is [indiscernible] contact and clearly published the been think as Pete record coming in will going which soon fairly update of to instrumental now.

Maury Raycroft

Got it.

my taking questions. Okay, thank you for

Peter Greenleaf

Thanks, Maury.

Operator

Thank you.

Oppenheimer. Our next today coming from from Kim is question Justin

Your line is now live.

Justin Kim

good for taking questions. afternoon. the Hi, Thanks

wondering the I there the sort the footprint you the commercial points, current Just the about about feels the how current of know so feel about gave grow team think could some launches the in-person about wondering during whether sort commercial to color how just the progress, when you is environment. team able team Max address forward? team is going how of size and heavy just touch it of and

Peter Greenleaf

and I what you sitting companies how a boards very that at that to – deployed Yes. of numbers can color have mean, companies sit what on opportunity higher today out we I other than work with I can how tell these other higher said live of that Max we are we I specialty previously more bit seeing there they that the access as interactions. or are comfortable getting feel types quite think we give I with. are against commercial from is that’s we are

Max so got you’ve are additional would encouraged I then thing and the by And if that. comments. we say I guess any last

that. fuel we needing to expand resources opportunity we that could opportunity to area a found we saw possibility of shift got or So resource certain we could we have an where there we was to do if the a saw

that couple weeks right. we to make anything of I enough the cash the learning out the sure launch do we to have balance we are Max, into on we we is in the answer ability adjustments short but have this deployed, put make, had first think there? us are think you to we the making are forethought I gives feel

Max Colao

it’s No, on. I think Yes. right

have point. we early the otherwise. of so I very really right this level deployment. got It’s at difficult to It’s assess think

Justin Kim

differences? thanks. through are target Got based your is launch to go, sort communications conversations of it. nephrologists? how rooms one the commercial from seeing you expected on it. Great, another wondering ending just and up between And just any with Got Maybe you rooms macro on level, to nephrologists different

Peter Greenleaf

Max, think I but in right jump is can short no, you detail. can love And And that. on the I more give he answer

Max Colao

the short no. Yes, answer is

those are specialties. We targeting

We prescribing seeing are targeting XX,XXX physicians specialties about as that both we specialties those across are is across and well.

Justin Kim

Okay, the the got variable it. And were maybe sort just of just question numbers R&D also is forward R&D right little of sort the quarter think a wondering, final on way sort the a go to spend? of number sort bit and also quarter-to-quarter side clarification OpEx of about fourth is

Peter Greenleaf

Miller? Joe

Joe Miller

Yes, thanks question. the Yes. for

as the today, continuation ongoing. there are of throughout So, studies call noted we kind

– in So a timing when you shift differences with QX if be towards be going speaking start saw some related directionally probably other what I but I the a consistent result overall, There when be R&D would will be directionally, think correct. will fairly related say might activities, in as forward. directionally, expenses there we of and fairly generally they but and trials,

Justin Kim

Thanks great. the taking Alright, questions. for

Peter Greenleaf

Thanks, Justin.

Operator

you. Thank

from today from question David coming Bloom Burton. next is Martin Our

line Your now live. is

David Martin

of know with treating for cases adding are are Yes. physicians you drug And that or are taking patients any voclosporin I you are one Benlysta early, set the a or set other? Benlysta they and one for where another it’s are decision questions. with to physicians making there Thank are the or if on voclosporin my seeing Benlysta? patients with all SLE, patients already treat but

Peter Greenleaf

Yes.

early trends we there where data So, I answer us Benlysta out paradigm. of into seeing fits treatment on those for be not be, the are actually to my think both and to the aggregating probably it’s would

Max hearing it me see be you actually don’t of think of stage Max, I game. my Neil let the if are has of might that this answer this any see as anything? good So, has any But hearing be, would have to been well. at much data comment we if and

Max Colao

we Look, questions questions. early just it’s good insights – have it’s too to yes, for don’t – your us to real are

We haven’t have are into post-surveys run we haven’t any even we we right. run yet given launch yet, scheduled, research that days XX but market many

So, are in insights but we will go of as good not those terms have there a along, insights. yet but we deep we question, it’s more that,

David Martin

Okay, have question. another I did

Sorry.

Peter Greenleaf

Neil, Yes. add? to anything

Neil Solomons

Benlysta early. combination, although No, I that too was hypothetically voclosporin, We I of going about lot people and but talk got that it’s [indiscernible]. the a in theoretically to even think combination about add the future

David Martin

Okay, post-marketing you what are thanks. to do? those? Peter, What obligations, are mentioned have you required

Peter Greenleaf

Yes.

we sort So, that about I formulate there do response mean, has more what FDA we what to do work had the or questions is further required and to are and of can we are whether going a on to not. decide

some do to go into of you just that want Neil, So detail? maybe

Neil Solomons

number to and study to interaction something as and adolescent pediatric then we see the also called well. in requirements [indiscernible] Yes, next terms – the anyway. study course of are presenting the is there we we of is is have trial, which which year report we like are which drug-drug well. one, things AURORA X pediatric the actually have as is There to are Those doing do would

So, doing at looking that. we are

David Martin

you. thank Okay,

Peter Greenleaf

Thanks, David.

Operator

question coming Thank from Wainwright. Arce Our [Operator is H.C. next you. today Instructions] Ed from

now is line Your live.

Ed Arce

thanks Great, taking my for questions.

of are signal So is variability that indication looks sort days that sort in indication have start with when launch, following good firstly, along RX important therefore start to and counts are some of help XX I provide of demand could just metrics very may this given the some there the have launch provide counts realized, of the and insight? the days, further that, actually before again, you a days, any to like? variability RX what for approval you value mentioned but out provide the do any past in sense But trend? other And yet. out can’t really a the early level early that How wondering, far you as before,

Peter Greenleaf

Yes.

in those access we I think add making are are policies etcetera, right I and what targets. now, will we that he calls a Max metrics looks see turn the color. work like are whether are the that high our amount mentioned but be looking we level over anymore on actually of payer that we many of following, at in to The to wants Max that second doing, if targets

indicators as actual also at. our not important over are and more think than and but to to to business policy everyone look that trends going look give be is days is I will color into look like XX just what like, leading that on are give coverage we more promise time, trends we we this prescription to think

ones are given have important in game. we this that the early today We think the

So and – the want I while everybody comfortable that should what the trends where target we giving feel of in tougher are albeit exact are from trend internal be. with think sure the prescription you and expect X centers are heard we we Day target not seeing terms physicians our it’s think we front, in expectations have just academic access make numbers been what I on our to with seeing said, is to numbers, above live, on it

of are those don’t early about out would We we good numbers really, throw to think think numbers too so be early. So, I just we indicative feel things. where it’s there, because

you would what Max, anyway, add? So

Max Colao

closely think specific the North developed only in other Right months. others will next I Shield now, Blue have is I follow we Carolina, we LUPKYNIS specific and policies. think sure payer the that of you going Blue thing very watching policy, – one many am coverage LUPKYNIS only to are be commented develop I Cross that’s perfectly, we coverage

Ed Arce

follow-up are coming Okay, aggregated I correctly, to million great. coverage an number Max, XXX And about couple you just that, targeting lives of and correct? that total or meetings next lives a of days, in of is with a total you confirm, payers up insured the heard would XXX said XX% have of represent million the then as few this that think I

Max Colao

The numbers add will the to XXX.

think XX We of up lined I it’s these another million have terms meetings. upcoming lives in

Ed Arce

just what next could for you then you first key what of looking are you for data And points with there, X, are up data in great. lastly, are expecting the us year you the what quarter coming and Okay, if remind measuring? AURORA

Peter Greenleaf

jump to detail? want just you in Thanks, the give Ed, Neil,

Neil Solomons

Yes.

it There a other our going at both be for not this stability is things people rates But So, yes renal prescribers. and the a huge arms was And present, to be period. going study data are look as be we drug safety compliance, to amount X-year I and that the – selling of as very output produce well, the trial. mean, think – it’s or clearly, this going primarily of like relapse over valuable function to primary obviously are where the commitment. to should continue should the such and are in people us that things that’s you there remind going from I other

Ed Arce

Fantastic. Thanks much. so

Peter Greenleaf

Thanks, Ed.

Operator

you. Thank

turn floor the session. We to closing over back of further to question-and-answer have comments. I’d or like reached the for end our Peter any

Peter Greenleaf

I to And you, afternoon. for Well, the thank all operator. thank on want you joining this call us

as updates Thank forward As providing to our you – year to And exciting company. be your for and can see, coming continued all XXXX the looking an I support over months. next evening. have the to well additional great continues looking you for will a am forward progress providing continue

Operator

today’s That and concludes webcast. you. Thank teleconference

your at thank you disconnect time participation day. today. this wonderful may and You a line have for your We

Aurinia Pharmaceuticals (AUPH) 25 Feb 212020 Q4 Earnings call transcript